Nuwellis (NUWE) AI Stock Analysis

• Market Cap: $2.43M
• Dividend Yield: N/A
• Average Volume (3M): 289.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: -8.93%
• EPS Growth: 97.80%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.56
• Shares Outstanding: 902,665
• 10 Day Avg. Volume: 82,161
• 30 Day Avg. Volume: 289,177
• PEG Ratio: 0.06
• Price to Book (P/B): 9.48
• Price to Sales (P/S): 7.08
• P/FCF Ratio: -6.41
• Enterprise Value/Market Cap: -0.87
• Enterprise Value/Revenue: -0.26
• Enterprise Value/Gross Profit: -0.42
• Enterprise Value/Ebitda: 0.28
• 1Y Price Target: $3.90
• Price Target Upside: 60.49% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(2.88% Upside)

Nuwellis' overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While there are positive corporate developments and strategic initiatives, the immediate financial challenges and bearish technical indicators weigh heavily on the stock's attractiveness.

Positive Factors

Pediatric Revenue Growth

Strong growth in pediatric revenues indicates increasing demand and successful market penetration in a specialized segment, supporting long-term revenue stability.

New Patent Issuance

The new patent strengthens Nuwellis' IP portfolio, enhancing competitive advantage and supporting future product innovation, particularly in pediatric care.

NIH Grant for Pediatric Device

The NIH grant supports critical development of pediatric devices, potentially expanding market reach and reinforcing Nuwellis' position in pediatric healthcare solutions.

Negative Factors

Overall Revenue Decline

A significant revenue decline poses challenges for financial stability and growth, necessitating strategic adjustments to reverse the trend and sustain operations.

Gross Margin Decrease

Reduced gross margins due to lower production volumes impact profitability, highlighting the need for cost management and operational efficiency improvements.

Increased Operating Loss

Rising operating losses indicate ongoing financial strain, underscoring the necessity for strategic cost reductions and revenue enhancement to achieve profitability.

Nuwellis Business Overview & Revenue Model

Company Description

Nuwellis, Inc. is a medical technology company focused on developing innovative solutions for the management of fluid overload in patients. Operating primarily in the healthcare sector, Nuwellis specializes in advanced medical devices and technologies that improve patient outcomes, particularly for those suffering from conditions like heart failure and other fluid management disorders. Their flagship product is the Aquadex SmartFlow system, which utilizes a unique ultrafiltration process to effectively remove excess fluid from the body, thereby addressing critical health challenges associated with fluid overload.

How the Company Makes Money

Nuwellis generates revenue primarily through the sale of its medical devices, particularly the Aquadex SmartFlow system and related disposables. Revenue streams include direct sales to hospitals and healthcare providers, as well as rental agreements for their devices. The company may also benefit from strategic partnerships with healthcare institutions and distributors to expand its market reach and improve product adoption. Additionally, Nuwellis could explore opportunities for reimbursement from insurance providers for the cost of its products and services, contributing to its overall revenue. Factors such as increasing demand for effective fluid management solutions and the growing prevalence of heart failure and related conditions further enhance the company's earning potential.

Nuwellis Financial Statement Overview

Summary

Nuwellis faces significant financial challenges marked by consistent losses and negative cash flows, despite stable revenue and a strong equity position. The company needs to focus on improving operational efficiency and profitability to ensure long-term sustainability.

Income Statement

Nuwellis demonstrates modest revenue growth with a 2.8% increase from 2022 to 2023 and a slight decline of 1.4% in 2024. However, the company is grappling with negative profitability as evidenced by significant negative EBIT and net income margins. Despite a decent gross profit margin of approximately 64.9% for 2024, ongoing losses due to high operational costs are concerning.

Balance Sheet

The company's balance sheet shows a healthy equity position with an equity ratio of 66.2% in 2024, indicating a strong buffer against liabilities. However, the debt-to-equity ratio stands at 0.08, showcasing manageable leverage but returns on equity remain negative due to sustained net losses. The stability is commendable, yet profitability remains a critical issue.

Cash Flow

Cash flow analysis reflects a challenging situation with negative free cash flow, although there is a marked improvement in operating cash flow from 2023 to 2024. The company's reliance on financing activities for liquidity is evident. Free cash flow growth remains negative, indicating ongoing cash burn issues which could impact future operations if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.17M	8.74M	8.86M	8.54M	7.92M	7.44M
Gross Profit	4.97M	5.83M	4.98M	4.75M	4.49M	4.06M
EBITDA	-7.53M	-10.53M	-16.36M	-4.90M	-19.06M	-16.65M
Net Income	-16.57M	-11.16M	-20.21M	-14.53M	-19.55M	-15.84M
Balance Sheet
Total Assets	7.98M	9.86M	9.77M	24.67M	30.42M	20.01M
Cash, Cash Equivalents and Short-Term Investments	3.09M	5.09M	3.80M	18.31M	24.20M	14.44M
Total Debt	383.00K	545.00K	760.00K	984.00K	1.18M	339.00K
Total Liabilities	4.07M	3.33M	6.56M	12.32M	4.47M	3.69M
Stockholders Equity	3.91M	6.53M	3.21M	12.36M	25.95M	16.32M
Cash Flow
Free Cash Flow	-9.41M	-9.65M	-18.18M	-15.27M	-18.06M	-16.87M
Operating Cash Flow	-9.28M	-9.59M	-17.94M	-15.15M	-17.84M	-16.57M
Investing Cash Flow	-125.00K	-60.00K	330.00K	14.73M	-15.72M	-267.00K
Financing Cash Flow	10.60M	10.96M	3.68M	9.42M	27.87M	30.02M

Nuwellis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUWE, the sentiment is Negative. The current price of 2.43 is below the 20-day moving average (MA) of 2.43, below the 50-day MA of 2.96, and below the 200-day MA of 19.29, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 45.28 is Neutral, neither overbought nor oversold. The STOCH value of 72.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUWE.

Nuwellis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PAVM	48 Neutral	$10.04M	0.32	20.03%	―	-99.28%	-46.16%
NUWE	45 Neutral	$2.43M	-0.08	-467.14%	―	-8.93%	97.80%
VTAK	41 Neutral	$3.38M	-0.03	-173.74%	―	82.96%	82.04%
HSCS	40 Underperform	$7.07M	-0.32	-193.24%	―	-66.40%	65.99%
AEMD	38 Underperform	$3.44M	-0.07	-191.39%	―	―	76.53%

Nuwellis Corporate Events

Nuwellis Appoints John L. Erb as Interim CFO

On October 7, 2025, Robert B. Scott announced his resignation as Chief Financial Officer of Nuwellis, Inc., effective around October 24, 2025. His departure is not due to any disagreements with the company. The company plans to initiate a search for a new CFO. On October 8, 2025, the Board appointed John L. Erb, the current President and CEO, as interim CFO starting on the separation date. Mr. Erb has extensive experience in the medical device industry and has held various leadership roles within Nuwellis and other companies. His appointment as interim CFO is not accompanied by any additional compensation or changes to his current plans.

Nuwellis Announces ULTRA-Peds Registry Findings

On September 30, 2025, Nuwellis, Inc. announced findings from the ULTRA-Peds registry, a multi-center observational study examining the real-world use of the Aquadex System in children with acute kidney injury (AKI), fluid overload, or congenital kidney failure.

Nuwellis Secures New Patent for Hemolysis Sensors

On September 18, 2025, Nuwellis, Inc. announced the issuance of a new U.S. patent related to hemolysis sensors in blood filtration systems, which supports their pediatric device, Vivian, and future innovations. This patent issuance strengthens Nuwellis’ intellectual property portfolio, potentially enhancing their market position and innovation capabilities in the medical device sector.

Nuwellis Secures NIH Grant for Pediatric Device Development

On September 9, 2025, Nuwellis, Inc. announced that the National Institutes of Health (NIH) awarded a multi-year grant of approximately $3 million to its partner, Koronis Biomedical Technologies Corporation. This grant will expedite the development of Vivian™, a pediatric continuous renal replacement therapy device, and enhance the company’s software and firmware, potentially strengthening its market position.